Skip to content

Arvinas ARVN Free cash flow margin

Free cash flow margin at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-378.7%+24.1pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-474%+92.4pp
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-45.8%-64.9pp
Immunome logo
ImmunomeIMNM
-5,118.9%-8,601pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-9,986.5%-4,727pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-207.2%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's free cash flow margin?
Arvinas (ARVN) reported free cash flow margin of -287.4% in Q1 2026.
What is the long-term trend for Arvinas's free cash flow margin?
Over 3 years (2020 to 2025), Arvinas's free cash flow margin has grown at a -34.3% compound annual growth rate (CAGR), from -371% to -105%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.